Sponsor: Tizona Therapeutics, Inc.
Sponsor Study ID: TTX-080-001
Study Title: A First in human, Phase 1 Study to Evaluate the Safety of TTX 080, an HLA G Antagonist, in Subjects With Advanced Solid Tumors
CTO #: 103396
NCT Number: NCT04485013
Phase: I
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Bladder; Breast; Cervix Uteri; Colon; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Melanoma, Skin; Other Female Genital; Other Urinary; Ovary
Study Objectives: This is a Phase 1, multicenter, open-label, multiple-dose, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, and pharmacodynamics of TTX-080 monotherapy in subjects with advanced or metastatic solid tumors known to express HLA-G. This first-in-human (FIH) study has been designed to evaluate the safety, tolerability, and preliminary antitumor activity of TTX-080 as monotherapy in adults with unresectable or metastatic solid tumors known to express HLA-G.